Synthesis and evaluation in rats of homologous series of [18F]-labeled dopamine D2/3 receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers

EJNMMI Research

Table 3 Quantitative results of in vitro autoradiography

Tracer	Tracer concentration, nM^a	Striatal SBR^b (% change relative to control condition)
Tracer	Tracer concentration, nM^a	Control	Raclopride	GTP
[¹⁸F]FEt-AMC13	0.9 ± 0.7 (n = 3)	3.40 ± 1.25	0.63 ± 0.53 (−81%)*	0.66 ± 0.52 (−81%)*
[¹⁸F]FPr-AMC13	1.4 ± 1.6 (n = 3)	2.07 ± 1.06	0.41 ± 0.23 (−80%)*	0.42 ± 0.23 (−80%)*
[¹⁸F]FBu-AMC13^c	0.2 (n = 1)	0.85 ± 0.23	0.10 ± 0.19 (−88%)*	0.20 ± 0.16 (−76%)*
[¹⁸F]FBu-AMC13^c	4.5 ± 3.6 (n = 3)	0.19 ± 0.18	0.04 ± 0.22 (−79%)	–
[¹⁸F]FEt-AMC15^c	5.8 ± 1.6 (n = 4)	1.64 ± 1.04	0.65 ± 0.37 (−60%)*	0.67 ± 0.28 (−59%)*
[¹⁸F]FPr-AMC15	5.0 ± 7.2 (n = 3)	1.01 ± 0.46	0.39 ± 0.22 (−61%)*	0.37 ± 0.24 (−63%)*
[¹⁸F]FBu-AMC15	2.3 ± 1.8 (n = 3)	0.69 ± 0.30	0.25 ± 0.23 (−64%)*	0.23 ± 0.23 (−67%)*

*p < 0.05 relative to control values, 2-sided Welch test
^aConcentrations are means ± SD from n independent experiments
^bSpecific binding ratio (SBR) values are means ± SD from the total number of slides (3–28 per condition) assayed in all experiments
^cPublished earlier [24]